?Product Name?: Ethyl 7-Chloro-1-cyclopropyl-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate (Ozenoxacin Intermediate A)
?CAS No.?: 103877-51-6

?? ?Product Overview?
A key intermediate in the synthesis of ?Ozenoxacin?, a non-fluorinated quinolone antibacterial agent. This compound is essential for pharmaceutical manufacturers producing broad-spectrum antibiotics targeting skin infections like impetigo. With a purity of ?≥99%? (HPLC), it ensures high-quality API production. Available in bulk quantities (1kg to 1000g) with stable inventory and prompt delivery.

?? ?Key Advantages?
? ?High Purity?: ≥99% (HPLC/GC certified) for API compliance.
? ?Stable Supply?: Multiple suppliers offer >1kg inventory with 2025 availability dates.
?? ?Strict QC?: Batch-specific COA, traceable synthesis pathways.

?? ?Applications?

1. ?Pharmaceutical Synthesis?: Critical for manufacturing Ozenoxacin (CAS 245765-41-7), used in topical treatments for Staphylococcus aureus and Streptococcus pyogenes infections.

2. ?R&D?: Supports development of novel quinolone-based antimicrobials.

?? ?Quality Certification?

• ?Test Methods?: HPLC, GC, NMR, and mass spectrometry.

• ?Standards?: Complies with ICH Q7 and ISO 9001 guidelines.

?? ?Market Trends?
The global demand for Ozenoxacin intermediates is rising due to expanding applications in dermatology and antibiotic resistance research. With Ozenoxacin’s patent expirations (2024-2034), generic drug production is projected to grow by ?12% CAGR? (2025-2030). Strategic partnerships with certified suppliers ensure competitive pricing and scalability.